Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11513/136
Tüm üstveri kaydı
Dublin Core AlanıDeğerDil
dc.contributor.authorYeşilova, Yavuz-
dc.contributor.authorÖzbilgin, Ahmet-
dc.contributor.authorTuran, Enver-
dc.contributor.authorSürücü, Hacer Altın-
dc.contributor.authorAksoy, Mustafa-
dc.date.accessioned2019-06-10T13:20:10Z-
dc.date.available2019-06-10T13:20:10Z-
dc.date.issued2014-
dc.identifier.otherDOI: 10.5152/tpd.2014.3829-
dc.identifier.urihttp://hdl.handle.net/11513/136-
dc.description.abstractClinical exacerbations were found in the patient being monitored in the dermatology clinic, 3 days after the start of systemic sodium stibogluconate treatment for cutaneous leishmaniasis (CL). The patient was the 5-year-old daughter of the first patient, who also had facial CL lesion, and the clinical exacerbation was seen on the 3rd day of treatment (systemic sodium stibogluconate) (Figure 1). This treatment was continued in both patients with the addition of 0.5 mg/kg prednisolone for 3 days. Rapid clinical recovery was shown in both patients with systemic corticosteroid (Figures 1d and 2d).en_US
dc.language.isoenen_US
dc.publisherTurkiye Parazitol Dergisien_US
dc.titleClinical Exacerbation Developing During Treatment of Cutaneous Leishmaniasis: An Id Reaction?en_US
dc.title.alternativeKutanöz Leishmaniasis Tedavisi Sırasında Oluşan Klinik Alevlenmeler: İd Reaksiyonu mu?en_US
dc.typeOtheren_US
Koleksiyonlarda Görünür:Dahili Tıp Bilimleri Bölümü

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
1. Clinical Exacerbation Developing During Treatment of Cutaneous.pdf95.93 kBAdobe PDFGöster/Aç


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.